ARCHIVES

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

FDA Committee IK IL-2/LAK For Modified Group C

May 1, 1987

Finasteride Improved Performance Of PSA In Prostate Cancer Prevention Trial

August 25, 2006

FASEB urges 10 percent increase for NIH in FY 2005.

January 23, 2004

NCI Projects Only 25% Of R01s Will Be Funded In FY89

November 25, 1988

Retraction Based On Data Given To Duke Last November, But Apparently Disregarded

October 29, 2010

White House Gives FDA Authority Over Tobacco Product Sales

August 18, 1995